BTN3A1 (Protein|Antibody|cDNA Clone|ELISA Kit)

All BTN3A1 reagents are produced in house and quality controlled, including 13 BTN3A1 Gene, 3 BTN3A1 Lysate, 3 BTN3A1 Protein, 1 BTN3A1 qPCR. All BTN3A1 reagents are ready to use.

Recombinant BTN3A1 proteins are expressed by HEK293 Cells with fusion tags as C-human IgG1-Fc, C-His, C-cleavage.

BTN3A1 cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each BTN3A1 of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.

BTN3A1 Protein (3)


BTN3A1 Protein, Human, Recombinant (ECD, Fc Tag)


Expression host: HEK293 Cells

Human BTN3A1 / CD277 Protein 10887

BTN3A1 Protein, Human, Recombinant


Expression host: HEK293 Cells

Human BTN3A1 / CD277 Protein 14489

BTN3A1 Protein, Human, Recombinant (His Tag)


Expression host: HEK293 Cells

Human BTN3A1 / CD277 Protein 14134

BTN3A1 cDNA Clone (13)


BTN3A1 qPCR Primer (1)

BTN3A1 Lysate (3)

BTN3A1 has the structure of a type I receptor of the Ig superfamily and is part of a family of seven BTN receptors encoded by genes in the MHC. BTN molecules are composed of two Ig domains (IgV, IgC2), a single transmembrane domain, and a large carboxyl-terminal domain termed B3.2 (or PRYSPRY) located in the cell cytoplasm. There are three human BTN3A loci, BTN3A1, BTN3A2, and BTN3A3, and clear orthologs of BTN3A molecules, now called CD277, are absent from the mouse genome. Despite its similarity to B7 molecules, BTN3A1 was proposed to act not as a coreceptor or costimulatory molecule, but rather to directly present pAg to the γδ TCR in a manner analogous to MHC-restricted peptide presentation. However, this model of BTN3A1 function has been challenged by conflicting data, which show pAg binding to a positively charged pocket in the cytosolic B3.2 domain, and that BTN3A1 does not directly engage the γδ TCR. This contradictory picture has emerged as a result of the complexity of the system and in particular by the use of endogenous and exogenous routes of Ag delivery in in vitro assays.Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy